SEC Company Response from TALPHERA, INC. (TLPH) (CIK 0001427925) (TLPH) — Feb 1, 2011
TALPHERA, INC. (TLPH) (CIK 0001427925)
Date: Feb. 1, 2011 · CIK: 0001427925 · Accession: 0001193125-11-020162
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-170594
Letter
Securities and Exchange Commission Division of Corporation Finance Dan Greenspan Sebastian Gomez Abero Re: AcelRx Pharmaceuticals, Inc. Registration Statement on Form S-1 (File No. 333-170594)
Dear Mr. Riedler:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as the representative of the underwriters, hereby join AcelRx Pharmaceuticals, Inc. in requesting that the effective date of the above-referenced registration statement be accelerated to February 3, 2011, at 2:00 p.m., Eastern Time, or as soon thereafter as practicable.
In connection with this acceleration request and pursuant to Rule 418(a)(7) and Rule 460 under the Act, please be advised that from January 20, 2011 through the date hereof, the undersigned effected the following approximate distribution of copies of the Preliminary Prospectus dated January 20, 2011:
0 to prospective underwriters;
250 to 250 institutional investors;
50 to 5 prospective dealers; and
25 to others.
This is to further advise you that the underwriters have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Remainder of Page Intentionally Left Blank]
Very truly yours,
PIPER JAFFRAY & CO.
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request VIA FACSIMILE AND EDGAR February 1, 2011 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-4720 Attn: Jeffrey P. Riedler Christine Allen Lisa Vanjoske Dan Greenspan Sebastian Gomez Abero Re: AcelRx Pharmaceuticals, Inc. Registration Statement on Form S-1 (File No. 333-170594) Dear Mr. Riedler: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as the representative of the underwriters, hereby join AcelRx Pharmaceuticals, Inc. in requesting that the effective date of the above-referenced registration statement be accelerated to February 3, 2011, at 2:00 p.m., Eastern Time, or as soon thereafter as practicable. In connection with this acceleration request and pursuant to Rule 418(a)(7) and Rule 460 under the Act, please be advised that from January 20, 2011 through the date hereof, the undersigned effected the following approximate distribution of copies of the Preliminary Prospectus dated January 20, 2011: 0 to prospective underwriters; 250 to 250 institutional investors; 50 to 5 prospective dealers; and 25 to others. This is to further advise you that the underwriters have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Remainder of Page Intentionally Left Blank] Very truly yours, PIPER JAFFRAY & CO. By: PIPER JAFFRAY & CO. By: /s/ Christie Christina Christie Christina, Authorized Officer as representative of the several underwriters cc: Richard A. King, AcelRx Pharmaceuticals, Inc. Mark B. Weeks, Cooley LLP Chadwick L. Mills, Cooley LLP David W. Pollak, Morgan, Lewis & Bockius LLP Albert Lung, Esq., Morgan, Lewis & Bockius LLP Signature Page to Acceleration Request Letter